Karyotypically distinct U251, U373, and SNB19 glioma cell lines are of the same origin but have different drug treatment sensitivities

Gene

Volumn 540, Issue 2, 2014, Pages 263-265

  Stepanenko, Alexey A ^a   Kavsan, Vadym M ^a  

^a Institute of Molecular Biology and Genetics   (United Kingdom)

Author keywords

Aneuploidy; Chromosome instability; Drug resistance; Glioblastoma; Karyotype

Indexed keywords

CEDIRANIB; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DASATINIB; ERLOTINIB; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PACLITAXEL; PROTEIN P53; QUERCETIN; SUNITINIB; TEMOZOLOMIDE;

CANCER RESISTANCE; CHROMOSOMAL INSTABILITY; COPY NUMBER VARIATION; GLIOMA CELL; HETEROZYGOSITY LOSS; IN VITRO STUDY; KARYOTYPE; LETTER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SHORT TANDEM REPEAT; SINGLE NUCLEOTIDE POLYMORPHISM;

ANEUPLOIDY; CHROMOSOME INSTABILITY; DRUG RESISTANCE; GLIOBLASTOMA; KARYOTYPE;

CELL MOVEMENT; CELL PROLIFERATION; HUMANS; NUCLEAR PROTEINS; RNA INTERFERENCE; RNA-BINDING PROTEINS;

EID: 84896543477     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.02.053     Document Type: Letter

References (31)

1. Abaan O.D., et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Research 2013, 73:4372-4382.
2. A'Hern R.P., et al. Taxane benefit in breast cancer - a role for grade and chromosomal stability. Nature Reviews. Clinical Oncology 2013, 10:357-364.
3. Brard L., et al. Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells. Drug Design, Development and Therapy 2009, 2:61-69.
4. Demichelis F., et al. SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines. Nucleic Acids Research 2008, 36:2446-2456.
5. Duesberg P., et al. Cancer drug resistance: the central role of the karyotype. Drug Resistance Updates 2007, 10:51-58.
6. Federici G., et al. Systems analysis of the NCI-60 cancer cell lines by alignment of protein pathway activation modules with "-OMIC" data fields and therapeutic response signatures. Molecular Cancer Research 2013, 6:676-685.
7. Fuxe J., et al. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A. Cell Growth & Differentiation 2000, 11:373-384.
8. Heng H.H., et al. Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective. Journal of Cellular Physiology 2009, 220:538-547.
9. Ikediobi O.N., et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Molecular Cancer Therapeutics 2006, 5:2606-2612.
10. Kubota H., et al. Identification of recurrent chromosomal rearrangements and the unique relationship between low-level amplification and translocation in glioblastoma. Genes, Chromosomes & Cancer 2001, 31:125-133.
11. Lee A.J., et al. Chromosomal instability confers intrinsic multidrug resistance. Cancer Research 2011, 71:1858-1870.
12. Li R., et al. Chromosomal alterations cause the high rates and wide ranges of drug resistance in cancer cells. Cancer Genetics and Cytogenetics 2005, 163:44-56.
13. Li Y., et al. PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. Cancer Research 2008, 2008(68):1723-1731.
14. Liu H., et al. mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Molecular Cancer Therapeutics 2010, 9:1080-1091.
15. Lorenzi P.L., et al. DNA fingerprinting of the NCI-60 cell line panel. Molecular Cancer Therapeutics 2009, 8:713-724.
16. Malla R.R., et al. Cathepsin B and uPAR knockdown inhibits tumor-induced angiogenesis by modulating VEGF expression in glioma. Cancer Gene Therapy 2011, 18:419-434.
17. Martinho O., et al. In vitro and in vivo analysis of RTK inhibitor efficacy and identification of its novel targets in glioblastomas. Translational Oncology 2013, 6:187-196.
18. McGranahan N., et al. Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Reports 2012, 13:528-538.
19. Moghaddas Gholami A., et al. Global proteome analysis of the NCI-60 cell line panel. Cell Reports 2013, 4:609-620.
20. Panner A., et al. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Molecular and Cellular Biology 2005, 25:8809-8823.
21. Patnaik S.K., et al. Expression of microRNAs in the NCI-60 cancer cell-lines. PLoS One 2012, 7:e49918.
22. Ramis G., et al. EGFR inhibition in glioma cells modulates Rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth. PLoS One 2012, 7:e38770.
23. Rasnick D. The Chromosomal Imbalance Theory of Cancer 2012, Taylor & Francis Inc., (342 pp.).
24. Reinhold W.C., et al. Cell Miner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Research 2012, 72:3499-3511.
25. Roschke A.V., et al. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Research 2003, 63:8634-8647.
26. See W.L., et al. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. Cancer Research 2012, 72:3350-3359.
27. Siegelin M.D., et al. Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. Neuro-Oncology 2009, 11:122-131.
28. Stepanenko A.A., Kavsan V.M. Evolutionary karyotypic theory of cancer versus conventional cancer gene mutation theory. Biopolym. Cell 2012, 28:267-280.
29. Stepanenko A.A., Vassetzky Y.S., Kavsan V.M. Antagonistic functional duality of cancer genes. Gene 2013, 529:199-207.
30. Timerman D., Yeung C.M. Identity confusion of glioma cell lines. Gene 2014, 536:221-222.
31. Zhao W., et al. Fatty acid synthase: a novel target for antiglioma therapy. British Journal of Cancer 2006, 95:869-878.